The distinct increase in HB-EGF in CSF of CIS patients was confirmed by a logistic regression model, demonstrating that HB-EGF concentration in the CSF of patients with MS is an effective discriminator between CIS versus non-CIS patients (Fig. 1f and Extended Data Fig. 1c). Here, HBEGF is linked to in situ carcinoma.